Processed cheeses with an antihypertensive effect greater than that of conventional cheese are provided in order to obtain a sufficient antihypertensive effect with a small intake. Specifically, processed cheeses with ACE inhibitory activity of 350 units per gram or more are manufactured using natural cheese such as cheddar cheese produced in New Zealand and Emmental cheese produced in Switzerland with ACE inhibitory activity of 420 units per grams or more. In addition, it is preferable to use low salt or unsalted natural cheese as a raw material, and use potassium salt as molten salt in order to make sodium content 990 mg or less per 100 g of processed cheese.